Guadecitabine plus ipilimumab in unresectable melanoma: five-year follow-up and integrated multi-omic analysis in the phase 1b NIBIT-M4 trial.
Noviello TMR, Di Giacomo AM, Caruso FP, Covre A, Mortarini R, Scala G, Costa MC, Coral S, Fridman WH, Sautès-Fridman C, Brich S, Pruneri G, Simonetti E, Lofiego MF, Tufano R, Bedognetti D, Anichini A, Maio M, Ceccarelli M.
Noviello TMR, et al. Among authors: bedognetti d.
Nat Commun. 2023 Sep 22;14(1):5914. doi: 10.1038/s41467-023-40994-4.
Nat Commun. 2023.
PMID: 37739939
Free PMC article.
Clinical Trial.